Genmab A/S (GNMSF) Revenue (2018 - 2026)
Genmab A's (GNMSF) quarterly Revenue came in at $896.0 million in Q1 2026, up 25.31% YoY from $715.0 million in Q1 2025, and down 66.34% on a QoQ basis from $2.7 billion in Q3 2025.
Genmab A/S (GNMSF) Revenue (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 6 years of Revenue data on file, last reported at $896.0 million in Q1 2026.
- Quarterly Revenue rose 25.31% year-over-year to $896.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 billion (up 20.72% YoY) and the FY2025 annual result came in at $3.7 billion, up 19.19% from the prior year.
- Revenue eased to $896.0 million in Q1 2026, from $2.7 billion in the prior quarter.
- In the past five years, Revenue ranged from a high of $2.7 billion in Q3 2025 to a low of $603.0 million in Q1 2024.
- A 3-year average of $1.4 billion and a median of $1.4 billion in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2025 — Revenue rose 18.57% — and 2026, when it climbed 25.31%.
- Tracing GNMSF's Revenue over 3 years: stood at $2.2 billion in 2024, then advanced by 21.11% to $2.7 billion in 2025, then slumped by 66.34% to $896.0 million in 2026.
- The last three Revenue figures came in at $896.0 million (Q1 2026), $2.7 billion (Q3 2025), and $1.6 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Bn |
| Mar 31, 2026 | 896.00 Mn |
| Sep 30, 2025 | 2.66 Bn |
| Jun 30, 2025 | 1.64 Bn |
| Mar 31, 2025 | 715.00 Mn |
| Sep 30, 2024 | 2.20 Bn |
| Jun 30, 2024 | 1.38 Bn |
| Mar 31, 2024 | 603.00 Mn |
| Sep 30, 2020 | 1,724,000.00 Bn |
| Dec 31, 2019 | 1.04 Bn |
| Sep 30, 2019 | 0.00 |
| Dec 31, 2018 | 598.60 Mn |